Skip to main content
Medical information Clinical review pending

Genetic Testing

Kras Nras

The KRAS/NRAS genetic test identifies mutations in the KRAS and NRAS genes, which can influence cancer treatment options, particularly targeted therapies. This test is important for guiding personalised cancer care.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Tumour tissue sample (biopsy or surgical resection). Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required for this test. The sample is typically obtained during a biopsy or surgery.
Test priceKSh 36,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Kras Nras test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients diagnosed with colorectal cancer
  • ✓Patients with other cancers where KRAS/NRAS mutations are relevant
  • ✓Individuals considering targeted cancer therapies
  • ✓Patients whose cancer treatment is not responding as expected
  • ✓Guidance for clinical trial enrollment
  • ✓Family history of certain cancers (discuss with doctor)
02

In plain language

What this test helps you understand

Identifies KRAS and NRAS gene mutations to guide targeted cancer therapy decisions, particularly in colorectal cancer. Helps predict response to specific treatments and supports personalised medicine approaches.
The KRAS/NRAS test is a specialised genetic analysis that looks for changes (mutations) in the KRAS and NRAS genes. These genes are involved in cell growth and division, and mutations in them are commonly found in certain types of cancer, especially colorectal cancer. Understanding if these mutations are present is crucial for doctors to determine the most effective treatment strategy for a patient. This test is particularly relevant for individuals considering targeted therapies, as the presence of specific mutations can predict how well these treatments might work.

This test specifically measures the presence or absence of mutations in the KRAS and NRAS genes within a patient's tumour sample. Identifying these mutations helps oncologists tailor treatment plans, potentially improving outcomes and reducing exposure to ineffective therapies.

Patients diagnosed with certain cancers, particularly colorectal cancer, are often recommended for this test. It may also be considered for individuals with other specific cancer types where KRAS or NRAS mutations are known to occur. Discuss with your doctor if this test is appropriate for your situation.

Taking this test can provide several benefits: - It helps guide decisions about using specific targeted therapies. - It can contribute to understanding the likely progression of the cancer. - It supports a personalised approach to cancer treatment. - It may provide information relevant to participation in clinical trials.

Results are interpreted by a qualified medical professional. A positive result indicates the presence of mutations, which may affect treatment choices. A negative result suggests that certain targeted therapies might be more effective. It is essential to discuss your results thoroughly with your healthcare provider to understand their meaning and implications for your care plan.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required for this test. The sample is typically obtained during a biopsy or surgery.
SampleTumour tissue sample (biopsy or surgical resection). Confirm specific requirements with the laboratory before booking.
MethodologyMolecular genetic testing, typically using techniques like Polymerase Chain Reaction (PCR) and sequencing to detect mutations in the KRAS and NRAS genes.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test only detects specific mutations in the KRAS and NRAS genes. It does not provide information about other genetic factors or mutations. Results should be interpreted in the context of the patient's overall clinical picture.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

KRAS and NRAS are genes that play a role in cell growth and division. Mutations in these genes can contribute to the development and progression of certain cancers.
This test helps identify mutations that can affect how cancer cells respond to specific targeted therapies. Knowing this helps doctors choose the most effective treatment plan.
A sample of the tumour tissue, usually obtained from a biopsy or surgery, is required for this test.
Confirm with the laboratory before booking.
A positive result means mutations were found, which may affect treatment options. A negative result suggests certain targeted therapies might be more effective. Your doctor will explain the results in detail.
Insurance coverage varies. Please check with your insurance provider regarding coverage for this specific test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp